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OBJECTIVE—The cortisol-regenerating enzyme 11b-hydroxys-
teroid dehydrogenase type 1 (11b-HSD1) ampliﬁes glucocorticoid
levels in liver and adipose tissue. 11b-HSD1 inhibitors are being
developed to treat type 2 diabetes. In obesity, 11b-HSD1 is in-
creased in adipose tissue but decreased in liver. The beneﬁts of
pharmacological inhibition may be reduced if hepatic 11b-HSD1
is similarly decreased in obese patients with type 2 diabetes. To
examine this, we quantiﬁed in vivo whole-body, splanchnic, and
hepatic 11b-HSD1 activity in obese type 2 diabetic subjects.
RESEARCH DESIGN AND METHODS—Ten obese men with
type 2 diabetes and seven normal-weight control subjects were
infused with 9,11,12,12-[
2H]4cortisol (40%) and cortisol (60%) at
1.74 mg/h. Adrenal cortisol secretion was suppressed with dexa-
methasone. Samples were obtained from the hepatic vein and an
arterialized hand vein at steady state and after oral administration
of cortisone (5 mg) to estimate whole-body and liver 11b-HSD1
activity using tracer dilution.
RESULTS—In obese type 2 diabetic subjects, the appearance
rate of 9,12,12-[
2H]3cortisol in arterialized blood was increased
(35 6 2 vs. 29 6 1 nmol/min, P , 0.05), splanchnic 9,12,12-
[
2H]3cortisol production was not reduced (29 6 6 vs. 29 6
6 nmol/min), and cortisol appearance in the hepatic vein after
oral cortisone was unchanged.
CONCLUSIONS—Whole-body 11b-HSD1 activity is increased in
obese men with type 2 diabetes, whereas liver 11b-HSD1 activity
is sustained, unlike in euglycemic obesity. This supports the con-
cept that inhibitors of 11b-HSD1 are likely to be most effective in
obese type 2 diabetic subjects. Diabetes 60:720–725, 2011
C
ortisol is an important regulator of energy ho-
meostasis, particularly in the liver and adipose
tissue (1). Cortisol levels in these tissues are
ampliﬁed by the 11b-reductase activity of the
enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-
HSD1), which regenerates cortisol from inert cortisone (2).
In rodents, 11b-HSD1 is a powerful determinant of met-
abolic health. For example, transgenic mice selectively
overexpressing 11b-HSD1 in adipose tissue develop obe-
sity, insulin resistance, hypertension, and dyslipidemia
(3,4). Similarly, mice overexpressing 11b-HSD1 in the liver
develop adverse metabolic features but do not become
obese (5). Obese rodents exhibit tissue-speciﬁc dysregu-
lation of 11b-HSD1, usually with upregulation in adipose
tissue and downregulation in liver (6,7). Selective 11b-
HSD1 inhibitors are efﬁcacious in several rodent models of
diabetes (8–11).
In humans, 11b-HSD1 also may be important to meta-
bolic health, and selective 11b-HSD1 inhibitors are in
development (11). Enzyme activity has been quantiﬁed
using a stable isotope tracer, 9,11,12,12-[
2H]4cortisol (d4-
cortisol), from which the 11-deuterium is removed during
interconversion with cortisone, allowing quantiﬁcation of
dilution of d4-cortisol by d3-cortisol and hence of 11b-
HSD1 activity, independently from the inﬂuence of other
cortisol-metabolizing enzymes (12). Substantial extra-adrenal
regeneration of cortisol by 11b-HSD1 has been detected in
the splanchnic circulation (13,14), arising mainly from
liver (15,16), and in subcutaneous adipose tissue (15). In
euglycemic obesity, numerous studies (17–19) have shown
that 11b-HSD1 mRNA and activity in subcutaneous adi-
pose tissue is increased, which has been corroborated in
vivo using microdialysis (20). Conversely, hepatic 11b-
HSD1 activity, assessed by measuring plasma cortisol after
oral administration of cortisone, is reduced in obesity
(17,19,21), although it is uncertain whether increased in-
activation of cortisone and cortisol by A-ring reductases in
the liver (22) contributes to the difference in plasma cor-
tisol. Increased cortisol clearance most likely explains why
morning cortisol levels are not elevated in obesity despite
increased cortisol secretion rates, as measured by urinary
cortisol metabolite excretion (19,23,24).
In obesity, a balance between 11b-HSD1 upregulation
in adipose tissue and downregulation in liver likely ex-
plains the lack of consistent changes in urinary cortisol–to–
cortisone metabolite ratios (25) or in whole-body cortisol
regeneration measured during d4-cortisol tracer infusion
(20,26). Whether such tissue-speciﬁc dysregulation occurs
in obese patients with type 2 diabetes is uncertain. This is
important, in particular because 11b-HSD1 inhibitors have
shown inconsistent efﬁcacy in phase II clinical studies in
patients with type 2 diabetes (11). If downregulation of
hepatic 11b-HSD1 occurs in type 2 diabetes, as it does
in euglycemic obesity, this may render type 2 diabetic
patients insensitive to enzyme inhibition. Indeed, this might
explain earlier observations that carbenoxolone, a non-
selective “prototype” 11b-HSD inhibitor, enhances insulin
sensitivity in healthy volunteers (27) and in lean patients
with type 2 diabetes (28) but not in obese patients (20).
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ORIGINAL ARTICLESurprisingly, few investigations of 11b-HSD1 have been
performed to date in obese patients with type 2 diabetes,
the likely target patient group for treatment with selective
11b-HSD1 inhibitors. Subcutaneous adipose tissue biopsies
suggest that 11b-HSD1 expression is increased in parallel
with the degree of obesity (29–32). Only one report (29)
describes hepatic 11b-HSD1 measured with the oral cor-
tisone test in type 2 diabetes in an unusual group of
patients who were not obese; although the area under the
curve was reduced, the initial rate of appearance of cor-
tisol was unchanged. Urinary cortisol–to–cortisone me-
tabolite ratios also are unchanged in type 2 diabetes
(29,33), as they can be in euglycemic obesity. The only
study (26) using deuterated cortisol tracer in type 2 di-
abetes found that whole-body and splanchnic 11b-HSD1
were unaltered, although, again, this group was not par-
ticularly obese (mean BMI 30 kg/m
2); comprised a mixture
of men and women (34); and liver 11b-HSD1 activity was
not measured speciﬁcally.
To resolve the question of whether obese patients with
type 2 diabetes have reduced 11b-HSD1 in the liver, we
examined whole-body, splanchnic, and liver 11b-HSD1 ac-
tivity by sampling from the hepatic vein during infusions of
9,11,12,12-[
2H]4cortisol tracer (12) in steady state and after
oral administration of cortisone.
RESEARCH DESIGN AND METHODS
Participants were male, aged 20–70 years, with normal full blood count and
normal renal, liver, and thyroid function. Subjects had no history of gluco-
corticoid therapy in the past year and an alcohol intake of ,21 units per week.
Two groups were recruited: healthy control subjects (BMI 20–26 kg/m
2) with
no signiﬁcant medical history or current use of any medication and men with
diet- or tablet-treated type 2 diabetes (BMI 30–40 kg/m
2). Local ethical ap-
proval and written informed consent were obtained.
Subjects were given 1 mg oral dexamethasone at 2300 h and fasted until
they attended the clinical research facility at 0730 h the following morning.
Measurements of blood pressure, height, weight, and waist and hip circum-
ference were taken.Abdominal subcutaneous andvisceraladipose content was
quantiﬁed by magnetic resonance imaging (MRI) using a 1.5T Gyroscan Intera
scanner (Philips Medical Systems, Shelton, CT), comprising 24 standardized
slices centered on the fourth/ﬁfth lumbar vertebrae encompassing L3-S1.
Cannulae (21G) were sited in the antecubital fossa of the right arm for infusion
and in a dorsal left-hand vein that was placed in a box heated to 60°C to achieve
arterialization for repeated blood sampling. Blood was taken for assessment of
fasting glucose and lipid proﬁle prior to a standard breakfast (total energy
content 2000 kJ, containing 60% carbohydrate, 15% protein, and 25% fat). An
infusion into the right antecubital vein was commenced 60 min later (t = 0),
which contained 60% unlabeled cortisol (Calbiochem, Nottingham, U.K.) and
40% 9,11,12,12-[
2H]4cortisol (d4-cortisol; Cambridge Isotopes, Andover, MA)
(at a rate of 1.74 mg/h for 6.5 h after an initial bolus of 3.5 mg [12]) and
dexamethasone (at 240 mg/h) to maintain adrenal suppression. At t = +30 min,
the right femoral vein was cannulated under local anesthesia (5 mL 2% lido-
caine), and a 7F Swan-Ganz catheter (Edward Lifesciences, Berkshire, U.K.)
was inserted into one of the hepatic veins under ﬂuoroscopic guidance for
sampling. From t = +120 min, indocyanine green (Pulsion Medical, Middlesex,
U.K.) was infused into the right antecubital vein at 30 mg/h to measure liver
blood ﬂow. After steady state was achieved (t =+ 1 8 0 –210 min), volunteers were
given an oral 5-mg cortisone tablet, and sampling continued until t = +330 min.
Laboratory analyses. Plasma cortisol, d4-cortisol, 9,12,12-[
2H]3cortisol (d3-
cortisol), cortisone, and d3-cortisone were measured by liquid chromatogra-
phy–tandem mass spectrometry, and serum indocyanine green was measured
by high-performance liquid chromatography, as previously described (15).
Serum liver function tests, lipids, albumin, and plasma glucose were measured
on an Olympus Diagnostics analyzer (County Clare, Ireland) using enzymatic
colorimetric methods. Corticosteroid-binding globulin (CBG) was measured
by radioimmunoassay (Biosource Technologies, Nivelles, Belgium). A1C was
measured by high-performance liquid chromatography on a Variant II analyzer
(Bio-Rad Laboratories, Hertfordshire, U.K.). Full blood count was measured
using a Sysmex XE automated analyzer.
Quantiﬁcation of abdominal fat mass. Image analysis of MRI scans was
performed using the biomedical imaging software suite Analyze version 9
(Mayo Clinic, Rochester, MN).
Kinetic analyses. Kinetic analysis in each subject was performed using the
mean of the seven samples obtained in steady state (ss) (t = +180–210 min).
Whole-body 11b-HSD1 activity was calculated from measurements in arte-
rialized (A) samples as previously described using Eqs. 1 and 2 (12):
Rate of appearance of cortisol ¼
d4-cortisol infusion rate
½d4-cortisol=cortisolA ss
2cortisol infusion rate ð1Þ




Clearance of d4-cortisol was determined by dividing the rate of infusion of
d4-cortisol by the arterialised d4-cortisol concentration (12). Hepatic blood
ﬂow was calculated as previously described (15). Splanchnic arterio-venous
(A-V) cortisol and d3-cortisol appearance were calculated using the principle
that tissue appearance = total appearance – arterial delivery to tissue (35). The
respective components were calculated as follows:










arterial delivery ¼ tissue blood flowss 3½traceeA

ss ð4Þ
By substituting d4-cortisol as the tracer and either cortisol or d3-cortisol as the
respective tracee, we derived equations to determine splanchnic (visceral
tissues and liver) 11b-HSD1 measured in arterialized and hepatic vein (HV)
samples using Eqs. 5 and 6 (14):




























Hepatic 11b-HSD1 activity in the non–steady state was estimated from the
conversion of orally administered cortisone to cortisol during the d4-cortisol
infusion by examining the enrichment of cortisol with d4-cortisol in the he-
patic vein from t = +210 min onwards. The change in cortisol concentrations in
the artery and hepatic vein after oral cortisone also was used as an index of
hepatic 11b-HSD1 activity.
Statistical analysis. All statistical analyses were performed using SPSS
version 14. All data were normally distributed on Kolmogorov-Smirnov tests.
Single measurements between groups were compared using unpaired t tests,
and measurements within individuals were compared using paired t tests. Dif-
ferences after cortisone administration were compared by two-way repeated-
measures ANOVA to examine changes with time and differences between
groups (control or obese type 2 diabetic subjects), with Bonferroni post hoc
testing as appropriate. P , 0.05 was considered signiﬁcant. Data are presented
as means 6 SEM. The study has 84% power to detect a 10% difference in the
whole-body rate of appearance of d3-cortisol, based on previous measure-
ments (15).
RESULTS
Subject characteristics. Anthropometric and biochemi-
cal measurements in 7 control subjects and 10 obese
type 2 diabetic patients are detailed in Table 1. Medi-
cations currently taken by the diabetic patients include
metformin (n = 8), a statin (n = 7), a sulphonylurea (n = 3),
an ACE inhibitor (n = 3), a thiazide diuretic (n = 3), a
calcium channel blocker (n = 2), a b-blocker (n = 2), as-
pirin (n = 2), an angiotensin 2 receptor antagonist (n = 1),
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higher systolic and diastolic blood pressure, fasting A1C,
plasma glucose, and g-glutamyltransferase concentrations;
lower HDL cholesterol; and increased subcutaneous and
visceral abdominal adipose tissue volume on MRI scan-
ning. Neither albumin nor CBG differed between groups.
Fasting plasma cortisol was similarly suppressed following
dexamethasone in both control and obese type 2 diabetic
groups (24 6 5 vs. 30 6 3 nmol/L), as was plasma cortisone
(5 6 1 vs. 8 6 1 nmol/L). The hepatic vein could not be
cannulated in one participant from the obese type 2 di-
abetic group; therefore, only data from the arterialized
samples in this individual were used for analysis.
Cortisol concentrations and kinetics in steady state.
Steady-state tracer concentrations and enrichments were
achieved after 180 min of d4-cortisol infusion (Fig. 1). At
steady state, plasma cortisol concentrations were similar
in the artery and hepatic vein in both groups (Table 2).
d4-Cortisol concentrations were lower in the hepatic vein
than the artery, in keeping with d4-cortisol metabolism
across the splanchnic tissues. d3-Cortisol was higher and
cortisone and d3-cortisone levels substantially lower in the
hepatic vein than in arterialized blood in both groups,
consistent with splanchnic 11b-reductase activity. There
were no differences in steady-state steroid concentrations
between control and obese type 2 diabetic patients.
Compared with control subjects, obese type 2 diabetic
patients had a similar steady-state whole-body rate of ap-
pearance of cortisol (79 6 6v s .6 06 12 nmol/min, P =
0.14) but a higher rate of appearance of d3-cortisol (35 6 2
vs. 29 6 1 nmol/min, P , 0.05) (Fig. 2) and also a trend for
increased d4-cortisol clearance (0.60 6 0.02 vs. 0.50 6 0.05
L/min, P = 0.05).
Hepatic blood ﬂow (1.0 6 0.1 vs. 1.1 6 0.2 L/min),
steady-state splanchnic cortisol release (50 6 6 vs. 58 6 13
nmol/min), and splanchnic d3-cortisol release (29 6 6 vs.
29 6 6 nmol/min) were not signiﬁcantly different between
control and obese type 2 diabetic subjects (Fig. 2).
Change in cortisol concentrations and d4-cortisol
enrichment after oral cortisone. After oral cortisone,
cortisol concentrations increased in the hepatic vein and,
to a lesser degree, in arterialized blood (Fig. 1A). There
was dilution of d4-cortisol by cortisol (P , 0.001) (Fig. 1B)
but no dilution of d4-cortisol by d3-cortisol; in fact, the
dilution by d3-cortisol decreased in both groups in arterial
and hepatic vein samples from 20 min after oral cortisone
(Fig. 1C). However, there was no signiﬁcant difference in
any of these variables between control and obese type 2
diabetic groups and no interaction between group and
time in repeated-measures ANOVAs (all P . 0.1).
DISCUSSION
These data show that whole-body cortisol regeneration by
11b-HSD1 is increased (by ~20%) in obese men with type 2
diabetes compared with lean control subjects. Splanchnic
11b-HSD1, measured as cortisol and d3-cortisol release
into hepatic vein in the steady state, was not different
between groups, while ﬁrst-pass conversion of cortisone to
cortisol in liver was similarly unchanged. We conclude
that, unlike in euglycemic obesity when liver 11b-HSD1 is
downregulated (17,19,21), in obese men with type 2 di-
abetes liver 11b-HSD1 is sustained. These observations
support the concept, inferred from earlier observations of
urinary cortisol–to–cortisone metabolite ratios (33), that
obese patients with type 2 diabetes lack compensatory
downregulation of 11b-HSD1 in liver and suggest that in-
tact pancreatic b-cell function is important in mediating
this compensatory response in euglycemic obesity. More-
over, these data suggest that there is plentiful 11b-HSD1
activity in liver as a target for selective 11b-HSD1 inhibi-
tion in obese hyperglycemic men.
Previous studies (17,19,21,29) examining liver 11b-HSD1
activity in vivo have relied on measurement of peripheral
plasma cortisol after oral administration of cortisone. Us-
ing this technique for total concentration, differences in
inactivation and clearance of cortisol may obscure differ-
ences in cortisol appearance; cortisol clearance tended to
be higher in the obese type 2 diabetic group in the current
study and has previously been shown to be increased in
obesity (23,36). The only previous report of plasma corti-
sol after oral cortisone administration in type 2 diabetes,
albeit in unusually lean patients, found that peripheral
cortisol was not different during the early time points after
cortisone ingestion, whereas cortisol concentrations were
lower in type 2 diabetes at later time points (29), consis-
tent with increased cortisol metabolism by other enzymes.
To minimize this confounding effect, we measured dilution
of d4-cortisol by cortisol in the hepatic vein. We also used
a lower dose of cortisone (5 mg) than previously (25 mg)
in order to avoid excessive dilution of tracer in the hepatic
vein. After correcting for baseline (steady state) differ-
ences by ANOVA, we found no differences between groups
in the appearance of cortisol in the hepatic vein or the
arterial circulation. As an aside, we also observed that the
ratio of d4-cortisol to d3-cortisol increased after oral cor-







Age (years) 47.5 6 6.0 52.3 6 2.9
Weight (kg) 76.1 6 3.5 109.7 6 3.6*
Height (m) 1.80 6 0.02 1.77 6 0.02
BMI (kg/m
2) 23.5 6 1.1 35.0 6 1.0*
Subcutaneous abdominal
adipose tissue volume (L) 1.69 6 0.27 4.27 6 0.34*
Visceral abdominal adipose
tissue volume (L) 0.94 6 0.13 2.96 6 0.28*
Systolic blood pressure
(mmHg) 133 6 4 151 6 5 †
Diastolic blood pressure
(mmHg) 76 6 28 7 6 2‡
Fasting plasma glucose
(mmol/L) 5.3 6 0.3 8.4 6 0.5*
A1C (%) 5.3 6 0.1 7.2 6 0.3*
Cholesterol (mmol/L) 5.3 6 0.3 4.7 6 0.2
HDL cholesterol (mmol/L) 1.5 6 0.1 1.2 6 0.1‡
Triglycerides (mmol/L) 0.8 6 0.1 2.3 6 0.6
Albumin (g/L) 44 6 04 4 6 1
Corticosteroid-binding globulin
(mg/L) 45 6 24 7 6 2
Alkaline phosphatase (units/L) 76 6 67 0 6 6
g-Glutamyltransferase (units/L) 23 6 54 5 6 5†
Alanine aminotransferase
(units/L) 23 6 43 9 6 6
Bilirubin (mmol/L) 12 6 11 1 6 1
Data are means 6 SEM for lean control subjects (n = 7) and obese
men with type 2 diabetes (n = 10). *P , 0.001; †P , 0.05; ‡P , 0.01
vs. lean control subjects.
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cant change in d4-cortisol concentrations. This is most
likely attributed to substrate competition between orally
administered cortisone and d3-cortisone for 11b-HSD1,
leading to a lower rate of appearance of d3-cortisol.
The oral cortisone administration was performed to
determine whether the hepatic component of splanchnic
activity was decreased in obese type 2 diabetic patients,
since we have previously suggested that visceral adipose
tissue may contribute a signiﬁcant proportion (approxi-
mately one-third) of splanchnic 11b-HSD1 activity (14)
and that increased visceral adipose activity could be bal-
anced by decreased hepatic 11b-HSD1 activity in obesity.
However, in two recent studies (15,16) involving portal
vein cannulation there was no evidence of extrahepatic
splanchnic 11b-HSD1 activity. Consistent with these data,
we found no discrepancy between hepatic (non–steady-
state) or splanchnic (steady-state) results. In our earlier
study, we modeled the data obtained from hepatic vein
samples after oral cortisone to derive estimates of the
contribution of liver and visceral adipose tissue to the
total splanchnic 11b-HSD1 activity (14). However, this
model relied on assumptions about portal vein concen-
trations of cortisone, which subsequent portal vein
sampling showed to be incorrect because of 11b-HSD2
activity in the gastrointestinal tract (15,16). For this rea-
son, we have not attempted to apply this model to the
current data.
FIG. 1. Plasma measurements during deuterated cortisol infusion. Data are means 6 SEM for lean control subjects (triangles, n = 7) and obese men
with type 2 diabetes (circles, n = 10 for arterial, n = 9 for hepatic vein) with plasma measurements in arterialized (open symbols) and hepatic vein
(ﬁlled symbols) samples. Cortisol (A), enrichment of cortisol with d4-cortisol (B), and d4-cortisol–to–d3-Cortisol ratios (C). Samples obtained
between t=+180 and t = +210 min were used to determine steady-state kinetics. Cortisone (5 mg) was administered orally after 210 min of the
deuterated cortisol infusion, and conversion to cortisol was measured over the following 120 min, with the change in d4-cortisol enrichment in the
hepatic vein used to measure 11b-HSD1 activity in the liver. By two-way, repeated-measures ANOVA from t = +210 min onwards with time and the
two groups as potential factors, the change in d4-cortisol enrichment with time in the hepatic vein was signiﬁcant in both groups from 10 min after
cortisone administration (P < 0.001); there was no signiﬁcant interaction between subject groups (control vs. obese type 2 diabetic subjects) and
time by ANOVA; therefore, post hoc testing was not performed. The d4-cortisol–to–d3-cortisol ratio and total cortisol also increased signiﬁcantly
in the hepatic vein in both groups after oral cortisone (P < 0.01 by ANOVA), again with no difference between groups. Similar changes were
observed in arterial samples, again with no difference between groups.
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generation is increased in type 2 diabetes is at odds with
the normal values reported in one previously published
article (26). In the previous study, splanchnic steady-state
d3-cortisol and cortisol release also were unaltered, as in
our data. However, the patients were not particularly
obese, with a mean BMI of 30 kg/m
2, whereas our subjects
had a higher mean BMI of 35 kg/m
2. This additional adi-
posity may be important in that it may contribute addi-
tional extrasplanchnic d3-cortisol generation from adipose
tissue, which may be sufﬁcient to increase whole-body
regeneration rates. Indeed, we have previously shown that
subcutaneous adipose tissue signiﬁcantly contributes to
total 11b-HSD1 activity in euglycemic obesity (15), making
this depot the most likely source of the increased whole-
body 11b-HSD1 in obese type 2 diabetic subjects. Other
tissues might also contribute to extrasplanchnic cortisol
release, including skeletal muscle (37), although previous
work (26) found no signiﬁcant d3-cortisol release across
the leg in type 2 diabetes.
We have previously suggested that chronic hyper-
insulinemia is responsible for the decreased hepatic 11b-
HSD1 in euglycemic obesity. Insulin decreases 11b-HSD1
in hepatocytes in vitro (38), while a low-carbohydrate diet
reduces fasting insulin concentrations and increases he-
patic 11b-HSD1 activity (39). Type 2 diabetes is a disorder
of relative insulin deﬁciency, which may account for lack
of downregulation of hepatic 11b-HSD1 in obese type 2
diabetic subjects. This appears to be at odds with previous
data (40,41) in humans showing that either an insulin in-
fusion or a mixed meal increases whole-body 11b-HSD1
activity, but this acute effect may operate primarily in
adipose tissue and may be posttranscriptional. Down-
regulation of 11b-HSD1 in the liver in euglycemic obesity
can be viewed as an adaptive process to decrease intra-
hepatic glucocorticoid concentrations (33); failure to de-
crease 11b-HSD1 in type 2 diabetes may result in increased
intrahepatic cortisol levels, which exacerbate the adverse
metabolic phenotype. Indeed, hepatic 11b-HSD1 mRNA
levels have been shown to correlate positively with serum
glucose concentrations in morbidly obese patients (42).
Obese type 2 diabetic patients in this study were taking
a variety of medications. None of these is known to alter
hepatic 11b-HSD1, and prescriptions varied widely among
our participants, but this remains a possible confounder.
Another potential confounder might arise if there were
differences between groups in the proportion of free and
protein-bound cortisol in plasma (43). There is evidence
that turnover of cortisol in the free pool is different from
that in the total plasma pool (44). However, serum CBG
and albumin concentrations were not different between
groups, indicating that the free cortisol pools are likely to
be similar in control and obese type 2 diabetic men.
To conclude, we have shown that obese men with type 2
diabetes, unlike euglycemic men (20,26), have increased
whole-body regeneration of cortisol by 11b-HSD1 and sus-
tained liver 11b-HSD1. Thus, it is justiﬁed to test the efﬁcacy
of selective 11b-HSD1 inhibitors in this group of patients.
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